Ten years of changes of top 10 best selling drugs in the world!

In the pharmaceutical industry, it is traditionally used to use the term "blockbuster drugs" as a benchmark to consider whether a drug can enter the elite drug echelon in the history of medicine The definition of "blockbuster drugs" is that the annual sales volume exceeds 1 billion US dollars We know that the heavy bomb strategy is a way to ensure that pharmaceutical companies achieve large-scale expansion, maintain competitive strength, and obtain huge R & D investment This also presents a reality that the pharmaceutical industry relies heavily on relatively small and expensive drugs for sales According to informa data, in 2018, the Top 180 companies in the pharmaceutical industry created $829 billion in drug sales (accounting for more than 95% of all global drug sales), basically representing the global pharmaceutical market capacity How important are the best selling drugs? Look at the data below: Top 10 drugs are sold by 16 pharmaceutical companies, with total revenue of 87.154 billion US dollars in 2018, accounting for 11% of the total sales of 180 companies; top 20 drugs are sold by 142.598 billion US dollars, accounting for 17% of the total; top 50 drugs are sold by 238.281 billion US dollars, accounting for 29% of the total From this data, we can see that the revenue of pharmaceutical companies mainly comes from these limited best-selling drugs, and the R & D investment of pharmaceutical companies has been shared with young partners before, such as IFPMA shared before A group of data is provided Among the 11 leading R & D companies in the world, 5 are pharmaceutical companies The pharmaceutical industry has invested $1498 billion in R & D every year, and the annual expenditure is even 5.5 times higher than that of national defense and aerospace industry! For individual companies, annual R & D investment of companies like Roche has exceeded 10 billion US dollars In this way, without the support of these blockbuster level best-selling drugs, pharmaceutical companies are unsustainable in the research and development of new drugs On the other hand, we can also see that in the last decade, many stubborn diseases have been overcome precisely because of the emergence of some new drugs Although limited best-selling drugs provide financial support for enterprise research and development, for many pharmaceutical enterprises, too much dependence on one or two best-selling drugs has also had an impact on the sustainable development of the company After all, drugs are limited by the patent period and have a life cycle According to statistics, the revenue in 2018 is most dependent on top 10 The top three best-selling drugs are Zaiyuan, Xinji and aibowei The heavyweight drugs, aliya, rifeme and Sumeria, have accounted for more than half of the company's total sales, 75.7%, 63.4% and 60.9% respectively Here is the comparison table of the best-selling drugs in 2018 and ten years ago You can feel the change (the standard is the drugs listed in 2009 and 2018 at the same time, unit: million dollars): the company name is not marked in the table above, you can also know which one is when you see these familiar names, top 10 The best-selling drugs are the golden eggs that every pharmaceutical company is dreaming of The purpose of investing heavily in R & D is to obtain these super heavy bomb drugs Of course, the emergence of such drugs has also improved human health and saved countless lives Although the annual sales volume of top 10 drugs is huge, if compared with other familiar products, the amount may not be so amazing For example, in the field of medicine, xiumeile is still the king in 2018, with an annual sales volume of 20.5 billion US dollars It's very powerful, but if it's compared with 31.9 billion US dollars Coca Cola and 16.7 billion US dollars iPhone, it's still a little brother.